Elekta Nomination Committee’s proposals for the 2013 Annual General Meeting

Stockholm, May 21 – The Nomination Committee of Elekta AB (publ) proposes that the 2013 Annual General Meeting elects Laurent Leksell as the new Chairman of the Board. Akbar Seddigh, who has been Chairman of the Board since 1999 and a Board member since 1998, has declined re-election. Laurent Leksell, who is the company’s largest shareholder, has been a Board member since 1972 and was the company’s President and CEO from 1972 to 2005.

“Elekta is very grateful for Akbar Seddigh’s board leadership over the past 14 years. Akbar’s guidance and his competence in medical technology and industrial expertise as well as his entrepreneurial spirit have contributed strongly to Elekta’s development and success,” says Laurent Leksell.

Tomas Puusepp, who has worked in senior positions at Elekta since 1988 and has served as the company’s President and CEO since 2005, is proposed as a new Board member. Tomas Puusepp will continue in his role as President and CEO.

Board members Hans Barella, Luciano Cattani, Siaou-Sze Lien, Wolfgang Reim, Jan Secher and Birgitta Stymne Göransson are proposed to be re-elected. The Nomination Committee’s proposals mean that there will continue to be eight Board members.

It is proposed that PwC be re-elected as the auditor, with Public Authorized Accountant Johan Engstam as auditor-in-charge.

The Nomination Committee’s proposals to the Annual General Meeting to be held on September 3, 2013, will be set out in full in the notification of the Annual General Meeting.

The Nomination Committee comprises:
• Laurent Leksell (Chairman) – personal shareholding and through companies
• Åsa Nisell – Swedbank Robur funds
• Ossian Ekdahl – First Swedish National Pension Fund, AP1
• Anders Oscarsson – AMF Insurance and Funds
• Akbar Seddigh – Chairman of the Board

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 6 5356 1242, email: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on May 21, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.


Documents & Links